首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   2287篇
  免费   153篇
  国内免费   61篇
耳鼻咽喉   6篇
儿科学   24篇
妇产科学   9篇
基础医学   374篇
口腔科学   38篇
临床医学   206篇
内科学   246篇
皮肤病学   107篇
神经病学   77篇
特种医学   53篇
外科学   123篇
综合类   196篇
预防医学   75篇
眼科学   17篇
药学   799篇
中国医学   108篇
肿瘤学   43篇
  2023年   29篇
  2022年   50篇
  2021年   69篇
  2020年   55篇
  2019年   70篇
  2018年   89篇
  2017年   87篇
  2016年   59篇
  2015年   63篇
  2014年   136篇
  2013年   262篇
  2012年   113篇
  2011年   169篇
  2010年   111篇
  2009年   82篇
  2008年   97篇
  2007年   96篇
  2006年   65篇
  2005年   77篇
  2004年   65篇
  2003年   69篇
  2002年   54篇
  2001年   43篇
  2000年   30篇
  1999年   37篇
  1998年   26篇
  1997年   23篇
  1996年   20篇
  1995年   30篇
  1994年   28篇
  1993年   17篇
  1992年   18篇
  1991年   16篇
  1990年   17篇
  1989年   21篇
  1988年   8篇
  1987年   10篇
  1986年   14篇
  1985年   29篇
  1984年   34篇
  1983年   21篇
  1982年   19篇
  1981年   17篇
  1980年   12篇
  1979年   8篇
  1978年   8篇
  1977年   8篇
  1976年   9篇
  1975年   6篇
  1974年   2篇
排序方式: 共有2501条查询结果,搜索用时 15 毫秒
1.
目的 比较新型口服硫酸盐溶液(OSS)和小剂量聚乙二醇(PEG)溶液对结肠镜检查质量的影响。方法 通过PubMed、Embase、Web of Science,搜索2000年1月-2020年12月发表的文章,使用Review Manager 5.4和Stata 12.0进行分析,比较新型OSS和小剂量PEG加维生素C(PEG + VC)溶液的肠道准备合格率、肠道准备优良率和不良反应发生率的差异。结果 6项研究共1 876名受试者符合纳入标准。在肠道准备合格率方面,OSS组和PEG + VC组比较,差异无统计学意义(93.4%和91.9%,RR^ = 1.02,95%CI:0.99~1.04,P > 0.05),OSS组的肠道准备优良率高于PEG + VC组,差异有统计学意义(50.2%和42.6%,RR^ = 1.18,95%CI:1.06~1.31,P < 0.05)。与PEG + VC组相比,OSS组恶心风险增加18.0%,差异有统计学意义(38.5%和32.6%,RR^ = 1.18,95%CI:1.05~1.33,P < 0.05),呕吐风险增加1倍以上(10.8%和4.7%,RR^ = 2.30,95%CI:1.63~3.23,P < 0.05)。Begg检验和Egger检验均未见明显发表偏倚。结论 使用新型OSS进行肠道准备,恶心和呕吐风险较低的患者有可能获得更好的肠道准备,因为与使用小剂量PEG溶液的患者相比,其增加了恶心和呕吐的风险。  相似文献   
2.
PurposeTo investigate the safety and efficacy of an aqueous polyethylene glycol-based liquid embolic agent, Embrace Hydrogel Embolic System (HES), in the treatment of benign and malignant hypervascular tumors.Materials and MethodsA prospective, single-arm, multicenter study included 8 patients, 5 males and 3 females, with a median age of 58.5 years (30–85 years), who underwent embolization in 8 tumors between October 2019 and May 2020. Technical success was defined as successful delivery of HES to the index vessel, with disappearance of >90% of the targeted vascular enhancement or, for portal vein embolization, occlusion of the portal branches to the liver segments for future resection. The volume of HES administered, ease of use (5 point Likert scale), administration time, and adverse events (AEs) were recorded. Evaluation was performed at 7, 30, and 90 days via clinical assessment and blood testing, and follow-up imaging was performed at 30 days.ResultsEight patients were enrolled, and 10 embolizations were performed in 8 lesions. Tumors included hepatocellular carcinoma (n = 4), renal angiomyolipoma (n = 3), and intrahepatic cholangiocarcinoma (n = 1). Technical success was 100%, and the average ease of use was 3.3 ± 1.0 SD. The HES delivery time was 1–28 minutes (median, 16.5 minutes), and the HES volume injected was 0.4–4.0 mL (median, 1.3 mL). All patients reached 30-day follow-up with imaging, and 6 patients reached 90-day follow-up. There were 3 serious AEs in 2 patients that were unrelated to the embolic agent.ConclusionHES resulted in a 100% embolization technical success rate. The product ease of use was acceptable, and no target vessel recanalization was noted on follow-up imaging at 30 days.  相似文献   
3.
4.
建立气相色谱法测定聚西托醇1000中残留的环氧乙烷、1,4-二氧六环、乙二醇、二甘醇和三甘醇等杂质,为聚西托醇1000生产质量控制提供参考。采用DB-1色谱柱检测环氧乙烷和1,4-二氧六环,顶空进样,进样口温度150℃,检测器温度250℃,顶空平衡温度70℃,平衡时间45 min。采用VF-17MS色谱柱检测乙二醇、二甘醇和三甘醇,液体进样,进样口温度270℃,检测器温度290℃。实验结果显示,环氧乙烷和1,4-二氧六环在各加样量范围内线性良好(r> 0.999),精密度RSD小于8.0%,平均回收率分别为90.6%和101.2%;乙二醇、二甘醇和三甘醇在3~60μg/mL内线性关系良好(r>0.999),精密度RSD小于3.0%,回收率均在96%~103%。本研究所建立的方法具有良好的专属性、线性、精密度和回收率,能够有效检测聚西托醇1000中多组分极微量杂质。  相似文献   
5.
6.
目的观察胃肠动力药莫沙必利联合二甲硅油散在慢性便秘患者行电子结肠镜检查前肠道准备过程中的应用效果。 方法选取徐州医科大学附属淮安医院拟行电子纤维结肠镜检查的慢性便秘患者300例,采用随机数字表法分为A组(复方聚乙二醇电解质散联合二甲硅油散)150例、B组(在A组的基础上联合莫沙必利口服)150例。采用Boston肠道量表进行肠道准备质量的评分、肠道气泡量表用于评估肠道内气泡的数量,并记录患者肠道准备时间,进镜时间及退镜时间、不良反应发生情况以及肠道疾病检出情况。 结果AB组2组实际完成肠镜检查过程分别为143例和146例,B组BBPS大于6分的比例明显高于A组(χ2=5.141,P<0.05);B组肠道泡沫量评中I、Ⅱ级所占比例明显高于A组(χ2=5.851,P<0.05)。且肠道准备所用时间、不良反应发生率及肠道病变检出率,B组也明显优于A组,差异有统计学意义(P<0.05)。 结论莫沙必利联合二甲硅油散作为肠道准备用药可以明显提高慢性便秘患者肠道清洁质量的同时显著减少肠腔内气泡的产生,也能减少肠道准备所用时间、降低不良反应发生率、提高肠道病变的检出率。  相似文献   
7.
Prion accumulation in the brain and lymphoreticular system causes fatal neurodegenerative diseases. Our previous study revealed that cellulose ethers (CE) have anti-prion activities in vivo and in prion-infected cells when administered at high doses. This study aims to improve the bioavailability of a representative CE using a liposomal formulation and characterized CE-loaded liposomes in cultured cells. The liposomal formulation reduced the EC50 dose of CE by <1/200-fold in prion-infected cells. Compared to empty liposomes, CE-loaded liposomes were taken up much more highly by prion-infected cells and less by macrophage-like cells. Phosphatidylserine modification reduced the uptake of CE-loaded liposomes in prion-infected cells and did not change the anti-prion activity, whereas increased the uptake in macrophage-like cells. Polyethylene glycol modification reduced the uptake of CE-loaded liposomes in both types of cells and reduced the anti-prion activity in prion-infected cells. These results suggest that a liposomal formulation of CE is more practical than unformulated CE and showed that the CE-loaded liposome uptake levels in prion-infected cells were not associated with anti-prion activity. Although further improvement of the stealth function against phagocytic cells is needed, the liposomal formulation is useful to improve CE efficacy and elucidate the mechanism of CE action.  相似文献   
8.
目的制备载紫杉醇的D-α-生育酚聚乙二醇1000琥珀酸酯(D-α-tocopheryl polyethylene glycol 1000 succinate,TPGS)修饰的羧甲基壳聚糖-大黄酸偶联物(PTX/TPGS-CR)纳米胶束,并对其进行初步评价。方法采用透析法,以载药量、包封率及粒径为指标,通过单因素考察优化PTX/TPGS-CR纳米胶束的制备工艺并进行验证。以溶血实验及血管刺激性实验初步考察PTX/TPGS-CR纳米胶束的安全性。四甲基偶氮唑盐微量酶反应比色法(MTT)法考察PTX/TPGS-CR纳米胶束对Hela细胞的毒性。通过激光扫描共聚焦显微镜定性和流式细胞仪定量考察Hela细胞对PTX/TPGS-CR纳米胶束的摄取情况。结果制备工艺优化后制得的PTX/TPGS-CR纳米胶束粒径为(197.3±4.4)nm,PDI为(0.131±0.021),电位为(-31.8±0.5)mV,载药量为(48.20±3.03)%,包封率为(87.26±4.91)%。溶血实验结果表明,其溶血率低于1.71%;血管静脉注射无明显刺激性。其对Hela细胞的杀伤作用具有浓度和时间依赖性,能被Hela细胞高效摄取。结论PTX/TPGS-CR纳米胶束载药量和包封率高,安全性好,其体外抗肿瘤活性稍优于Taxol?。  相似文献   
9.
BACKGROUND Bowel preparation in children can be challenging.AIM To describe the efficacy, safety, and tolerability of sodium picosulfate, magnesium oxide, and citric acid(SPMC) bowel preparation in children.METHODS Phase 3, randomized, assessor-blinded, multicenter study of low-volume, divided dose SPMC enrolled children 9-16 years undergoing elective colonoscopy. Participants 9-12 years were randomized 1:1:1 to SPMC ? dose × 2, SPMC 1 dose × 2, or polyethylene glycol(PEG). Participants 13-16 years were randomized 1:1 to SPMC 1 dose × 2 or PEG. PEG-based bowel preparations were administered per local protocol. Primary efficacy endpoint for quality of bowel preparation was responders(rating of ‘excellent' or ‘good') by modified Aronchick Scale. Secondary efficacy endpoint was participant's tolerability and satisfaction from a 7-item questionnaire. Safety assessments included adverse events(AEs) and laboratory evaluations.RESULTS 78 participants were randomized, 48 were 9-12 years, 30 were 13-16 years. For the primary efficacy endpoint in 9-12 years, 50.0%, 87.5%, and 81.3% were responders for SPMC ? dose × 2, SPMC 1 dose × 2, and PEG groups, respectively. Responder rates for 13-16 years were 81.3% for SPMC 1 dose × 2 and 85.7% for PEG. Overall, 43.8% of participants receiving SPMC 1 dose × 2 reported it was ‘very easy' or ‘easy' to drink, compared with 20.0% receiving PEG. Treatment-emergent AEs were reported by 45.5% of participants receiving SPMC 1 dose × 2 and 63.0% receiving PEG.CONCLUSION SPMC was an efficacious and safe for bowel preparation in children 9-16 years, with comparable efficacy to PEG. Tolerability for SPMC was higher compared to PEG.  相似文献   
10.
目的:观察揿针、聚乙二醇4000散联合生物反馈疗法治疗功能性便秘的临床疗效。方法:选取102例功能性便秘患者,按随机数字表法分为对照组和观察组各51例。对照组采用揿针联合聚乙二醇4000散治疗,观察组在对照组基础上加用生物反馈疗法治疗。观察患者治疗后便秘症状改善情况及肛门直肠动力、肛门直肠感觉和生活质量的变化,比较2组临床疗效。结果:观察组总有效率96.08%,高于对照组的80.39%(P<0.05)。治疗后,2组便秘症状评分均较治疗前降低,观察组便秘症状评分低于对照组,差异均有统计学意义(P<0.05)。治疗后,2组直肠最低敏感量、最大耐受量、直肠顺应性均较治疗前降低,观察组以上3项指标值均低于对照组,差异均有统计学意义(P<0.05)。2组治疗前后直肠静息压、肛门括约肌压力比较,差异均无统计学意义(P>0.05)。治疗后,2组躯体不适、心理社会不适、担心和焦虑、满意度及总分均较治疗前降低,观察组躯体不适、心理社会不适、担心焦虑、满意度及总分均低于对照组,差异均有统计学意义(P<0.05)。结论:揿针、聚乙二醇4000散联合生物反馈疗法治疗功能性便秘,可改善患者的便秘症状、肛门直肠动力、肛门直肠感觉及生活质量,提高治疗效果。  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号